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With breast cancer affecting one out of every nine women. 
in the United States in their lifetime and a 50% 
mortality rate among those who have the disease, efforts 
have been initiated to find a prophylactic regimen which 
would decrease a women's chances of developing breast 
cancer. ·The central purpose of this study was to 
characterize the influence of moderate levels of exercise 
on the induction and development of estrogen dependent 
and independent rat mammary tumors. This 
characterization was compared against the known 
antiestrogenic effects of tamoxifen. The tumor model 
used was 7,12-dimethylbenz(a)anthracene (DMBA) induction 
of rat mammary cancer. Hormone dependency was determined 
by observing tumor growth following oophorectomy. 
Although the results of the experiments yielded no 
indication of tumor inhibition due to the exercise 
ii 
regimen, rats treated with tamoxifen showed a significant 
reduction in body weight and mammary tumorigenesis. In 
the control group, an equal number of hormone-dependent 
and ho~mone~independent tumors were·seen following 
removal of the ovaries. In the ·exercise group, a 
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Table 1: Group tumor data for pre-oophorectomy 31 
tumor bearing rats (TBR). 
Table 2: Group tumor data for post-oophorectomy 32 
tumor bearing rats (TBR). 
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With one out of eight women developing breast 
cancer, mammary carinoma is the most common form of 
cancer affecting women in the United States. Since 1980, 
the~e had been a steady 2% increase in the incidence of 
breast cancer, but recently the incident rate has leveled 
off at approximately 182,000 new cases per year. The 
prevalent use of mammography for early detection during 
this period is believed to be responsible in part for the 
rise. The balance of cause for the rise remains unknown. 
Approximately 46,000 women per year will die from a 
metastatic progression of the disease (American Cancer 
Society 1994). 
In light of the inability to lower the mortality 
rate, attention and effort of scientists and clinicians 
has turned toward reduction of the incidence of breast 
carcinomas (Bernstein et al., 1992; Kelsey 1993). New 
prognostic techniques (Gail et al., 1989) and the 
discovery of the breast cancer linked genes, BRCAl and 
BRCA2, (Miki et al., 1994; Furteal et al., 1994; Wooster 
et al., 1994) have facilitated the possiblity that women 
with a higher individual risk could be targeted for 
prophylactic treatment. 
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A proposed intervention strategy involved the use of 
the adjuvant therapeutic agent tamoxifen, which had been 
succesfully used to prevent tumor recurrence in breast 
cancer patients (NATO, 1985). Tamoxifen, a non-steroid 
antiestrogen, blocks the stimulatory effects of estrogen, 
which is considered the primary promoter in estrogen-
dependent and early, estrogen-independent tumor cell 
lines. Due to tamoxifen's demonstrated ability to 
suppress recurrence in cancer patients, the Breast Cancer 
Prevention Trial was initiated to compare benefits of 
tamoxifen's prophylactic use versus the possible side 
effects in women who are assessed to have a high risk of 
developing breast cancer (Bush & Helzhlsouer 1993; 
Kelsey, 1993; NSABP, 1992). 
An alternate strategy of prevention has been a 
proposed alteration in lifestyle factors associated with 
breast cancer. Changes in components of everyday life, 
such as diet and exercise, have been the focus of many 
researchers because a concern over the ramifications of 
sustained hormonal manipulation (Bernstein et al, 1993). 
Exercise has received attention because laboratory and 
epidemiological evidence has shown an associated 
reduction in breast cancer incidence. Despite this 
evidence, little is known about the cause and effect of 
2 
the relationship between exercise and breast cancer 
incidence. 
Breast Cancer 
Breast carcinomas originate from the transformation 
of the epithelial cells which line the lobules and ducts 
of the breast. Seventy to eighty percent of breast 
tumors are ductal in origin (American Cancer Society, 
1987). 
Transformation occurs when the cell's genome is 
altered resulting in a failure of the mechanisms which 
regulate the cell cycle. In order for a tumor to develop 
from a single transformed cell, cell division must occur. 
Each cell cycle results in the passing on the altered 
chromosome, compounding the damage to the chromosome 
and/or altering chromosomal distribution. Cell division 
in tissues like the mammary epithelium is influenced by 
endogenous hormones or exogenous analogs. Epidemio-
logical observations, such as the increased risk 
associated with early menarche, late first full-term 
pregnancy, and the use of postmenopausal estrogen 
replacement therapy, indicate that ovarian hormones have 
a central role in the initiation and promotion of breast 
cancer (Am. Red Cross, 1994). Menstrual cycling and 
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pregnancy events are marked by large changes in the 
ovarian hormones estrogen and progesterone (Berstein & 
Ross, 1993). 
Growth of the mammary tissue occurs during two 
hormone dependent events, puberty and pregnancy. 
Although both processes are stimulated by estrogen, 
progesterone, insulin, cortisol, and prolactin, the 
timing and concentration of exposure to these hormones 
result in the distinct changes occurring between the 
events. Estrogen has a key role in puberty where it 
potentiates the action of prolactin and its concentration 
directly influences the growth and development of mammary 
tissue (Speroff et al., 1994). In the animal models, 
estrogen has been demonstrated to have a direct effect on 
mammary epithelial cell development by stimulating growth 
and branching (Silberstein et al., 1994; Halsam, 1988; 
Daniel et al., 1987). 
Estrogen- and progesterone-dependent changes in 
mammary tissue occur during normal menstrual cycles. 
During late luteal phase, stimulation by elevated levels 
of estrogen and progesterone results in maximal breast 
size. Increases in fluid secretion, mitotic activity 
and gene expression of nonglandular tissue and glandular 
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epithelium mark this period of size increase in the 
luteal phase (Speroff et al., 1994). 
The predominant estrogens circulating in the blood 
are estradiol-17P and estrone. Estradiol-17Phas been 
demonstrated to be the most biologically active form of 
estrogen in mammary tissue (Pasqualini, et al, 1991). 
During premenopausal years, almost all estrogen is 
ovarian in origin with estadiol-17P in higher plasma 
concentrations than estrone. After menopause, direct 
production of estrogen by the ovaries ceases. Most 
postmenopausal estrogen arises from the aromatization of 
adrenal androgens to estrone. In turn, some estrone is 
metabolized into estradiol. The postmenopausal plasma 
·concentrations of estrone are significantly higher than 
estrogen (Bernstein & Ross, 1993). 
Mammary tumors are normally characterized in part by 
estrogen dependence or independence. Measurements of the 
level of estrogen receptors in tumors are used in 
prediction of patient prognosis and viability of 
antiestrogen adjuvant therapy. Though clinical assays 
can produce qualitative and quantitative measurements of 
tumor ER, tumor hormone sensitivity does not correlate 
precisely with estrogen receptor status. Over 60% of 
human breast tumors are estrogen receptor positive (ER+) 
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and only two-thirds of these ER+ tumors are expected to 
be controlled by antiestrogen therapy. Further, 5-10% of 
estrogen receptor negative (ER-) assayed tumors have 
proven to be sensitive to antiestrogen therapy 
(Pentrangeli et al., 1994; McClelland et al., 1987; 
McClelland et al., 1986; Osborne et al., 1980; DeSornbre & 
Jensen, 1980; Paridaens et al., 1980; Wittliff et al., 
1980). Despite the discrepancy between ER status and 
estrogen sensitivity, the value _of the ER assay was 
elucidated by the relativity low percentage of ER+ cells 
in normal tissue, which is less than 20 percent (Ricketts 
et al., 1991; Peterson et al., 1987). Petrangeli et al. 
(1994) studying breast carcinoma biopsies found a 
significantly higher percentage of ER+ postive cells in 
neoplastic tissues (75%) compared to perineoplastic 
tissue (57%), and that there was a positive association 
between ER expression and ER gene hypomethylation. 
Normal methylation of the estrogen receptor gene can 
inhibit the expression of the receptor. The elevated 
expression of the ER in neoplastic tissue indicates the 
significance of estrogen in the pathogenesis of most 
breast cancers. 
Through interaction with the estrogen receptor, 
estrogen mediates many cellular activities essential for 
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tumor growth. Estrogen triggers DNA synthesis and gene 
transcription in normal and cancerous mammary cell lines. 
Release of growth stimulating, autocrine and paracrine 
polypeptides, such as tranforming growth factor-a, 
epidermal growth factor (Bates et al., 1988; Imai et al., 
1982), insulin-like growth factor-II (Brunner et al., 
1993; Osborne et al., 1989)and platelet-derived growth 
factor (Rosengurt et al., 1985.), has been shown to be 
increased with estrogen stimulation. Conversely, a 
reduction in the levels of the inhibitory factor, 
transforming growth factor-~ was affected by estrogen in 
the tumor cells (Knabbe et al., 1987). 
Animal studies have demonstrated that estrogens have 
a positive influence on the induction and promotion of 
mammary tumors in animal studies and that reversal of 
this influence can be achieved by oophorectomy or 
treatment with antiestrogens (Doa, 1981; Jordan, et al, 
1990; Jordan et al 1980). 
Epidemiological studies have shown that breast 
cancer risk increased in women having frequent, 
relatively short menstrual cyles (Pike et al., 1993; 
Whelan.et al., 1992; Henderson et al., 1985). Women 
with these frequent ovulatory cycles are believed to be 
at higher risk because more of their reproductive years 
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are spent in the luteal phase than women having less 
frequent ovulatory cycles. The high mitotic activity 
that marks the luteal phase is considered to be the 
source of the elevated risk. Consquently, women who 
experience anovulation or amenorrhea are shown to have a 
reduced risk of mammary cancer (Pike et al., 1993; 
Whelan.et al., 1992). 
Mechanism of Steroid Action 
The mechanism of steroid action can be demonstrated 
by the pathway of agonism of the estrogen hormones 
(Fiqure 1). Estrogen influences the activity of the 
target cell through a mechanism centered around the 
nuclear, estrogen receptor (ER). The hydrophobic, 
estrogen molecule is carried to mammary tissue by a sex 
hormone binding globulin (SHBG). The estrogen molecule 
becomes biologically active by dissociating from SHBG and 
diffusing through the lipid bilayer of the plasma 
membrane. The steroid passes through the cytosol and 
transverses the nuclear membrane. In the nucleus, the 
estrogen binds to the ER altering the conformation of the 
receptor (Figure 1). This comformational change causes 
the release of a heat shock protein and activates the 
receptor. The activated ER-estrogen complex then 
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dimerizes with another activated ER-estrogen complex. 
The dimer binds to the estrogen response element (ERE) on 
the target chromosome. Dimer binding to the ERE and 
interaction with RNA polymerase promotes the 
transcription of the estrogen-mediated gene downstream. 
The products of these genes potentiate the actions 












Figure 1: Mechanism of steroid action modified from Tsai 
and O'Malley (1994). SHBG=sex steroid binding 
globulin, HSP=heat shock protein, mRNA= 




Tamoxifen (Fig. 2), [ZJ-2-[4-(1,2-diphenyl-1-
butenyl)-phenoxyl]-N,N-dimethylethanamine, is a non-
steroid, antiestrogen first synthesized in 1966 (Harper 
MJK & Walpole AL, 1966). During the 1970s, it was 
discovered that tamoxifen demonstrated antiestrogenic and 
Figure 2: Tamoxifen molecule. 
represents hydrogen 
a hydroxyl group in 
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Functional group R 
in the basic molecule and 
trans 4-hydroxy-tamoxifen. 
antitumor behavior in rat models (Jordan, 1974; Cole et 
al., 1975; Nicholson & Golder, 1975; Jordan et al., 1978) 
and humans (Cole et al., 1971). Since then, numerous 
trials have shown tamoxifen's ability to decrease cancer 
recurrence and patient mortality rates (Bush & 
Helzlsouer, 1993). In recent years, tamoxifen has been 
proposed as prophylactic breast cancer agent for use by 
women, who have family history or genetic disposition 
toward developing a mammary carcinoma. 
The chemopreventative properites of tamoxifen have 
been demonstrated in animal models. Jordan et al, (1976) 
noted a reduced tumor number and increased time of 
appearance in a DMBA-induced mammary tumor model with use 
of tamoxifen. Parallel observations were made in the 
nitrosomethylurea (NMU)-induced mammary carcinoma model 
(Turcot-Lemay & Kelley, 1980). Long term tamoxifen use 
has been demonstrated to suppress tumor genesis (Jordan 
et al., 1991). Further, tamoxifen reduced by 90% the 
number of spontaneous tumors in a study of older rats 
(Maltoni et al., 1988). 
Tamoxifen has been shown to be an effective 
antitumoral and chemopreventative agent in mammary 
tissue. Elucidation has shown that it is a cytostatic 
agent, not a cytotoxic agent (Jordan, 1994). Studies in 
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vitro with human cancer cells, such as the MCF-7 cell 
line, have shown that tamoxifen inhibits transition from 
the G0-G1 phase resulting in suppression of cell cycling. 
This cytostasis produces an increase in the number of 
cells in G0-G1 phase and a decrease in number of cells in 
S, G2, and M phase in the cell cultures (Taylor et al., 
1983; Sutherland et al., 1983; Osborne et al., 1983). 
Using 3 [H]-thymidine assays, Osborne et al. (1992) showed 
that preneoplastic cell lines were less proliferative in 
an animal under a tamoxifen protocol. Additionally, 
removal of tamoxifen therapy from animals that have been 
transplanted with a cancer cell line resulted in the 
appearance of tumors (Jordan et al., 1991). 
The cytostatic influence on cancer development when 
tamoxifen is used prophylactically may select against 
estrogen-responsive cells producing a higher percentage 
of the more aggressive, estrogen-independent tumors. 
Zimniski and Fendl (1992) studying animals receiving 
coincidental doses of tamoxifen and a carcinogen 
witnessed a reduction in the total tumor incidence and 
100% selection of hormone-independent tumors. Sylvester 
et al. (1987) showed an 3-fold increase in the percentage 
of estrogen-independent tumors in a study with a 
prophylactic dosage of tamoxifen in a DMBA rat model. 
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With respect to tamoxifen's antitumoral properties, 
interaction with the estrogen receptor is central to the 
antiestrogens influence. While tamoxifen has a very low 
affinity for the ER, one of its metabolites, trans 4-
hydroxy-tamoxifen (Figure 2), has an affinity for the ER 
nearly equal to that of estradiol (Kemp et al., 1983). 
The binding of the receptor by the metabolite blocks the 
agonistic activities associated with normal estrogen-ER 
interaction (Jordan et al., 1977; Allen et al., 1980; 
Borgna & Rochefort, 1981). Molecular analysis has shown 
that the tamoxifen molecule fits into the estradiol 
binding pocket on the ER. The pocket contains a number 
of hydrophobic residues and a glutamate residue. The 
phenolic group of 4-hydroxytamoxifen occupies the same 
position relative to the hydrophobic groups as the A-ring 
of estradiol, but the glutamate residue is unable to 
hydrogen bond with the antiestrogen molecule. The long 
nitrogen-containing side chain inhibits interaction 
between arginine and aspartate residues of the ER 
necessary for its activation (Lewis et al, 1995). This 
positioning in the ER blocks estradiol binding without 
activating the receptor. Estrogen-related gene 
activation is blocked by the tamoxifen-ER complex, which 
is not capable of dimerizing with other activated 
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complexes and blocking estrogen-ER mediated cell 
stimulation. 
Exercise 
Exercise has been demonstrated to have beneficial 
effects on a number of disease processes, such as those 
of cardiovascular disease, diabetes, osteoporosis, and 
colorectal cancer (Friedenreich and Rohan, 1995). These 
observations have raised a debate as to whether or not 
exercise would have an influence on the processes that 
govern the etiology of cancer. The influence of exercise 
on the disease processes of breast cancer is believed to 
be due to the 1) alterations in the energy balance, 2) 
endocrine system effects; and 3) stimulation of the 
immune system (Thompson 1992). The influence on breast 
cancer has been studied in both animal and 
epidemiological studies. 
Exercise is physical activity specifically designed 
to improve physical fitness. There are three primary 
components of physical activity: duration, the length of 
the exercise bout; intensity, the work-rate of the 
exercise bout; and frequency. Aerobic exercise is 
characterized by a duration of at least 15 to 20 minutes; 
a frequency of at least 3 to 4 times a week; and an 
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intensity that will lead to improvement of aerobic 
capacity. Aerobic capacity cdn be measured by an 
improvement in maximal oxygen consumption, 
V0
2
max. (Caspersen, 1989). 
In the rodent model, the effect of exercise during 
tumor initiation (commonly considered to be the first 
seven days after carcinogen administration (Thompson, 
1994) and/or promotion phases of tumor development have 
been tested. Exercise begun during the initiation phase 
has been shown to decrease tumor incidence (Yedniak et 
al., 1987; Sakamoto et al., 1992; Moore and Tittle, 1973) 
or have no effect (Thompson, 1994). Studies with 
exercise protocols beginning during the promotional phase 
have yielded either decreases (Cohen et al., 1992; 
Bennick et al., 1986; Cohen, et al., 1988; Thompson, 
1994; Thompson et al., 1995) or increases (Thompson et 
al., 1988; Thompson et al., 1989) in the proportional 
incidence of tumors in the animals. The discrepancy in 
experimental results may be due to differences in 
protocols with respect to duration and intensity. Energy 
balance, endocrine, or immunological alterations may be 
subject to the demands of the protocol. 
Caloric expenditure of an exercise bout is a 
function of the duration and intensity of the activity. 
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As the caloric expenditure rises, the greater the effect 
it has on the body's energy balance. Thompson (1992) 
demonstrated a negative relationship between caloric-
expenditure and tumor indicidence. However, this 
assertion is challenged by the fact that in two studies 
Thompson et al. (1988; 1989) found no significant changes 
in carcass size or composition. Additionally, the purely 
caloric basis theory was confounded by the experiments of 
Thompson et al. (1995), which demonstrated a link between 
intensity and reduced tumor incidence. In that study 
carcinogenesis inhibition required an intensity that was 
70% maximal and had no correlation with caloric 
expenditure. This last study suggests that there is an 
intensity threshold where caloric expenditure has a 
greater influence on mammary carcinogenesis (Thompson et 
al., 1995) 
Another explanation for the discrepancy between the 
studies may be related to the altering of endocrine 
function. Thompson et al., (1995) stated that the 
duration of exercise had a greater effect than intensity 
on lengthening the animals' estrous cycle. A study using 
exercised rats which monitored varying intervals, 
indicated that extensive exercise induced changes in the 
frequency of release and strength of gonadotropin 
17 
releasing hormone and lutenizing hormone leading to 
amenorhea (Manning and Bronson, 1991). The expected 
luteal dysfunction or amenorhea resulting from the 
changes in the release patterns would lead to a 
significant reduction in levels of estrogen stimulating 
the mammary tissue and carcinomas. 
Most epidemiological studies in humans have 
generated results favoring the role of exercise or high 
levels of physical activity in the reduction of breast 
cancer risk, but contradictory evidence does exist. A 
study of the alumnae of 10 American colleges showed a 
decreased risk for athletes when compared to non-athletes 
(Fisch et al., 1987). Other studies focusing on the 
breast cancer risk when compared with the level of 
caloric expenditure showed a decreasing incidence in 
breast cancer as the caloric demand of exercise increased 
(Bernstein et al., 1994; Friedenreich and Rohan, 1995). 
Further studies have shown that women in occupations with 
a high level of physical activity also benefited from a 
lowered incidence of breast cancer (Zheng et al 1993; 
Vena et al., 1987). In opposition to these observations, 
the Farmingham Heart Study (Dorgan et al., 1994) and the 
American Cancer Society's Cancer Prevention (Garfinkel 
and Stellmanm, 1988) cohort studies observed an 
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increased risk of breast cancer with increased physical 
activity. 
During reproductive years, exercise has been shown 
to alter the pattern of regular menstrual cycling leading 
to a reduction in breast cancer incidence. Prospective 
studies where menstrual cycling characteristics were 
studied before and after training, demonstrated that 
exercise, especially strenuous exercise, can induce 
anovulation and luteal dysfunction, oligomenorrhea, and 
amenorrhea (Greene, 1993; Loucks, 1990; Keizer and 
Rogol, 1990). These interruptions of the menstrual cycle 
are believed to be the result of alterations in the 
hypothalamic-pituitary-ovarian axis, which lead to 
changes in levels and pulsatile release of GnRH and LH 
(Thompson, 1992; Greene, 1993; Loucks, 1990; Keizer and 
Rogol, 1990). 
Problem Statement 
The objective of this _study was to establish the 
influence of a moderate exercise regimen on the induction 
and growth of 7,12-dimethylbenz(a)anthracene induced, 
estrogen-dependent and.independent rat mammary tumors. 
Parallel protocols involving the use of tamoxifen served 
to assess the reduction of tumor incidence and influence 
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on estrogen dependence of exercise. Estrogen dependence 
was determined by changes in tumor volume preceeding and 
following oophorectomy. 
Hypothesis 
Prophylactic regimens of exercise and tamoxifen will 
inhibit the induction and growth of mammary tumors 
induced by the introduction of 7,12-dimethylbenz(a) 
anthracene (DMBA). Specifically, exercise will have a 
broad inhibition on both estroge_n-dependent and 
independent tumor cells; tamoxifen will have an 
influence on tumor growth and development with a greater 
effect on the estrogen-dependent tumors; and the two 
regimens in combination will have an additive effect on 
the inhibition of mammary tumor induction and growth. 
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METHODS AND MATERIALS 
Animals 
Forty-two female, Sprague Dawley rats (Harlan 
Sprague Dawley, Inc.) between 32-34 days of age, were 
housed two per cage in the Lappin Hall Animal Care 
Facility. They were placed on a 12 hour light/ 12 hour 
dark photoperiod. The rats were fed Purina Rodent Chow 
(Ralston Purina Company) and water ad libitium. The 
animals were maintained in the Lappin Hall Animal Care 
Facility. 
Prior to the experiment, the animals were randomly 
divided and segregated into four groups: Group I-10 rats 
in the control group; Group II-11 rats in the exercise 
group; Group III-10 rats in the tamoxifen group; and 
Group IV-11 rats in the tamoxifen & exercise group. 
Group I was administered both the exercise sham and 
tamoxifen sham protocols. Group II underwent the 
moderate exercise and sham tamoxifen protocols. Group 
III received the experimental tamoxifen regime and sham 
exercise. Group IV was maintained on active exercise 
and tamoxifen protocols (Figure 3.) 
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DAY 
1-10 -3 0 86 100 
Control (N=lO) - - -
' 
- - - - _., - - ---
Exercise (N=ll) 
Tamoxifen (N=lO) - l - - - - - - -I 
Tamoxifen-Exercise (N=ll) 
~ - .. - - - - - - -
' . ' . ' .. ' .. ' . 
(D 0 0 0 
Figure 3: Flow chart of research protocol by day. 1. Begin 
exercise protocols. 2. Begin tamoxifen protocols. 




Rats of the Group II and Group IV were placed on a 
moderate exercise regimen (Thompson, et al, 1989) ten 
days before the introduction of carcinogen. The animals 
were exercised on a motorized treadmill (Lafayette 
Instruments, Inc.) using electric shock as motivation. 
The established regimen consisted of five, 15-minute 
exercise bouts per week with a belt speed of 20 meters 
per minute and inclination of 1°. To introduce the 
animals to treadmill running, the first five days of the 
experiment were marked by increasing speed and duration: 
day one (day -10 with respect to carcinogen introduction) 
at 8 meters/minute, 3-5 minutes; day two at 12 
meters/minute, 10 minutes; day three at 12 meters/minute, 
15 minutes; days four and five at 16 meters/minute for 15 
minutes. The animals were run during the light period to 
insure that the activity was extracurricular to normal 
activity. This protocol was continued to the day 100 
when the animals were sacrificed (Fig. 3). 
Group I and Group III were maintained on sham 
treatment. The sham treatment involved placing the 
animal's cages into direct light for 15 minutes. This 
was done to equalize the stress of the control animals 
with those exercising on the unshaded treadmill. 
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Tamoxifen 
The Group III and Group IV were started on a 
prophylactic regimen of tamoxifen citrate three days 
before carcinogen introduction. Each animal was 
administered 100 micrograms of tamoxifen citrate (Sigma 
Chemical Co.) in 0.1 ml peanut oil vehicle (Sigma 
Chemical Co.) five days a week (Osborne, 1992). After 
being suspended in a peanut oil vehicle using vigorous 
stirring, tamoxifen citrate was administered to the rats 
via subcutaneous injection using a 1.0 ml tuberculin 
syringe and 26 gauge needle. The tamoxifen protocol was 
continued until the animals were sacrificed (Fig 3). 
Groups I and Group II were given subcutaneous 
injections of 0.1 ml of peanut oil on a schedule 
synchronous with the tamoxifen-administered groups. 
Carcinogen Administration 
On experimental day O, the animals (age 
approximately 49-50 days) received 10 mg dose of 7,12-
dimethylbenz(a)anthracene (Sigma Chemical Co.) dissolved 
in 1.0 ml of sesame oil (Sigma Chemical Co.). After 
light etherization, each animal was administered the DMBA 




The date of carcinogen introduction was marked as 
day 0 with respect to the initiation of tumor 
development. Four weeks after the administration of DMBA 
introduction, the animals were checked daily for palpable 
tumors. Newly discovered tumors were recorded on the 
basis of individual rat identity, date of discovery and 
anatomical position. 
Oophorectomy 
Eighty-six days after carcinogen administration, an 
oophorectomy was performed on those animals with palpable 
tumors. All animals were anesthetized using 4 mg of 
sodium pentobarbital per 100 gm of body weight (Sigma 
Chemical Co.) dissolved in 0.1 ml distilled H20. The 
ovaries of tumor bearing rats (TBR) were removed via 
bilateral, dorsal incision. The animals were given four 
days to rest before resumption of tamoxifen and exercise 
regimens. 
Tumor Measurement and Comparison 
While anesthetized, the tumors of TBRs were measured 
using Vernier calipers. Measurements of the diameter 
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were taken for each tumor along three major axes and 
volumes calculated using the following equation: Volume= 
4/3*n*Radiusl*Radius2*Radius3. The calculated volumes 
were compared to ones taken two weeks later at sacrifice 
(Day 100). A decrease in tumor volume of greater than 
20% over the two week period was given to indicate 
estrogen dependency (Fendl & Zimniski, 1992). 
Statistical Analysis 
Statistical evaluation of the experimental data were 
tested for significance using the Student's t-test a 
level of significance of p<0.05. 
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Pre-Oophorectomy 
Mean Animal Mass 
RESULTS 
Animals were weighed on day 86 just prior to 
oophorectomy. Comparison of the mean group masses showed 
a significant difference between the values for groups 
receiving the tamoxifen protocol and those that were 
receiving the peanut oil control (Figure 4). Larger mean 
masses were seen in the Group I (Control) and Group II 
(Exercise), which had 254g +/- 7.4g and 254g +/- 7.0g, 
respectively. Rats in Group III (Tamoxifen) and Group IV 
( Tamoxifen-Exercise) showed mean group masses of 211g 
+/- 7.7g and 203g +/- 6.4g. Cross comparisons using 
Student's t-test indicated a significant difference 
(p<0.05) between either Group I or Group II groups and 
Group III or Group IV. 
Tumor Appearance 
During the period between carcinogen introduction 
and oophorectomy, animals were examined for palpable 
tumors. Tumor appearance data for the experimental 

























a=significant difference from control group at p<0.05 
b=significant difference from exercise group at p<0.05 
Figure 4: Mean animal mass of the control, exercise, 
tamoxifen, and tamoxifen-exercise groups 86 
days after DMBA adminstration. 
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number of tumor bearing rats (TBR) per group (Figure 5). 
Animals were added to the respective group's cumulative 
number of tumor bearing rats at the date of appearance of 
the first palpable tumor. 
Group I yielded the most tumor bearing rats with 
six of ten animals having developed tumors during the 
observation period. The first palpable tumor appeared 47 
days after carcinogen introduction. The remaining five 
animals had first tumors palpated at day 52; day 53, two 
rats; day 59 and day 73. 
Five out of eleven animals palpated tumors in the 
Group II. First tumor appearance date for the exercise 
group was on day 53. The other four Exercise group tumor 
bearing rats palpated tumors on day 55, day 58, day 61 
and'day 70. 
During the pre-oophorectomy observation period, the 
Group III had one tumor bearing rat in the experimental 
group of ten. This animal had the earliest palpable 
tumor appearance date, day 41. 
The Group IV had one tumor bearing rat out of eleven 














28 35 42 49 56 63 70 77 
Days Following Carcinogen Introduction 
Figure 5: Control, exercise, tamoxifen, and tamoxifen-
exercise rats with palpable tumors based on 
the day of first tumor appearance 
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Group Tumor Information 
Tumor data for experimental groups was accumulated 
for pre-oophorectomy period. Groups were compared on the 
basis of tumor bearing rats per group, average number of 
tumors per TBR, and total number of tumors (Table 1). 
There was found to be a significant difference in TBR per 
group between the either Group I or Group II and Group 
III or Group IV with respect to TBR per group. 
Table 1: Group tumor data for pre-oophorectomy tumor 
bearing rats ( TBR) . 
TBR per Tumors Tumors per 
Group per TBR Group 
Control 6/10 2.17 13 
(n=l O) 
Exercise 5/11 1.20 6 
(n=ll) 
Tamoxifen 1/loa,b 1.00 1 
(n=lO) 
Tam-Ex 1/11 a,b 1.00 1 
(n=l 1) 
a=significant difference from the control group at p<0.05 




Group Tumor Information 
Post-oophorectomy tumor data for the experimental 
groups were collected on the sacrifice date. The values 
were similar to that of pre-oophorectomy with a few 
exceptions (Table 2). The Group I had two tumors arise 
in an animal that had been oophorectomized. An 
unoophorectomized animal in the Group III developed a 
tumor on day 90. Finally, a loss of three animals while 
under anesthesia diminished the size of the Group II from 
eleven to eight animals. No significant differences were 
found with statistical analysis. 
Table 2: Group tumor data for post-oophorectomy tumor 




























Estrogen Dependence and Independence 
Determination of estrogen dependence or independence 
of tumors was done by a comparison of pre-oophorectomy 
tumor volume measurements with the post-oophorectomy 
volumes which were measured at sacrifice. Indication of 
estrogen dependence was established by a 20% decrease in 
volume over the two-week period (Fendl & Zirnniski, 1992). 
Tumors that appeared in the oophorectomized Group I 
animal were perceived to be estrogen independent because 
of their growth in an estrogen poor environment. The 
late ~rising tumor in the unoophorectomized Group III 
animal could not be classified. Additionally, no 
determination could be made for the tumors of the dead 
Group II animals. 
Compiled estrogen dependence/independence data for 
the experimental group showed mixed results (Table 3). 
Group I animals were divided nearly equally between 
independent and dependent tumors. Even if the two late 
appearing tumors were disqualified, the division would 
still remain nearly equal with 7 dependent and 6 
dependent tumors. With this trend in evidence, a fifty-
fifty distribution between dependence and independence 
was used for assessment of the other tumor distributions. 
Analysis of the Group II tumor distribution was 
significantly hindered by the loss of the three animals 
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and their collective four tumors. The remaining animals 
showed a prevalence toward the development of estrogen 
dependent tumors (Table 3). 
The Group III had just one tumor bearing rat. This 
rat had developed an estrogen dependent tumor, which 
seemed unusual in the presence of the antiestrogen 
tamoxifen. 
The Group IV had a single tumor bearing animal with 
one tumor. The estrogen independent classification of 
this tumor met expectations in this tamoxifen-treated 
animal (Table 3). 
Tab~e 3: Assessment of estrogen dependence and 




























* One tumor developed in this animal that had not been 
oophorectomized. 
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Estrogen Dependence Vs. Appearance Time 
Comparison of estrogen status, dependent or 
independent, with palpable-tumor appearance time yielded 
no observable trend. An examination of only the Group I 
distribution and appearance times also failed to yield 




The infuence of exercise on the estrogen levels in 
the body and on the estrogen dependent/independent status 
of developing mammary tumors is largely unclear except 
for menstrual and ovarian cycle changes resulting from 
regimens involving intense, extended physical activity 
(Greene, 1993; Loucks, 1990; Keizer and Rogol, 1990). 
The estrogen dependent effects of moderate exercise 
levels remain uncharacterized. 
Sustained exercise is considered to be an essential 
component in proper weight control programs, but in this 
study, the tamoxifen protocol not the exercise protocol 
was associated with a significantly lower body weight 
when compared to the controls (Figure 1). The observed 
lack of change in the exercise group body weight is 
consistent with other studies where no significant change 
in rat body weight and composition was seen in animals on 
similar exercise protocols when compared to controls 
(Thompson et al., 1988; Thompson et al.,1989). In 
looking at tamoxifen's effect of body weight, Wade and 
Heller (1993) observed that tamoxifen in dose-dependent 
fashion reduced body weight. They attribute this 
phenomena to a dose-dependent hypophagia; a decreased 
lipoprotein lipase activity, the blocking of estrogen 
receptors in adipose tissue, the associated reduction in 
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amount of adipose tissue; and as yet an uncharacterized 
interaction with the ER receptor in the brain and 
throughout the body. Examination of the body mass data 
from this study has indicated that tamoxifen's effects on 
body mass in the rat models are more pronounced than 
those of moderate exercise. 
Tamoxifen's antiestrogenic and antitumoral 
properties led to its use in adjuvant breast cancer 
therapy and consideration for use in prophylaxis. The 
group tumor data demonstrated the antitumoral activity 
with the tamoxifen protocol producing a significant 
reduction in the number of tumor bearing animals within 
the respective groups when compared to the exercise and 
control groups (Table 1). In contrast to the 
antiestrogenic activity, a mixed result was seen in tumor 
dependence. As would be expected, the single TBR of 
Group IV (tamoxifen and exercise) developed an estrogen 
independent tumor, but the Group III (tamoxifen) TBR had 
one estrogen dependent tumor (Table 2). The dependent 
tumor's resistance to tamoxifen may be the result of 
estrogen receptor mutation, sequestering of tamoxifen by 
an antiestrogen binding sites, or metabolism of tamoxifen 
to a less antagonistic isomer (Osborne and Fuqua, 1994; 
Jordan, 1994; Pavlik et al., 1992). Development of 
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resistant tumors is one of the chief concerns in use of 
tamoxifen prophylaxis. 
As the body adapts to exercise, marked changes in 
metabolism occur. One of the expectations of this study 
was to determine whether these adaptations have an 
influence on the tumor growth and induction. When 
compared to the control group data, the pre-oophorectomy 
numbers for the exercise group indicated that there was a 
decreased number of tumors per tumor bearing rat. 
However, in looking at the number of TBR per group or the 
first tumor appearance times of those tumors, the 
difference is less prominent. These differences in tumor 
pre-oophorectomy tumor data could be a result of altered 
hepatic metabolism associated with exercise which would 
effect the oxidase-dependent activation of the 
procarcinogen DMBA (Thompson, 1994; Dssing, 1985; 
Rosenblooom and Sutton, 1985). 
Unfortunately, the loss of three out of five tumor 
bearing animals in exercise group compromised the most 
novel objective of this study, the determination of the 
influence of moderate exercise on the endocrine 
sensitivity of breast tumors. The tumors in surviving 
animals were both estrogen dependent. If this partial 
observation was evidence of the whole, it would favor a 
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mechanism of influence for exercise which is not 
integrally related endocrine activity. Continuing the 
supposition based on the partial result, it is apparent 
that if the exercise protocol favored the development of 
estrogen dependent tumors, tamoxifen's effects as 
demonstrated in combination group overrode this selective 
influence. 
A certain amount of ambiguity surrounds the study of 
the effects of exercise on mammary tumor etiology because 
of the broad physiological changes and adaptations that 
result from an extended regimen of exercise. The aim of 
this study was to establish the influence of a moderate, 
prophylactic exercise regimen on estrogen-dependent and 
independent rat mammary tumors and to assess this 
influence using parallel prophylactic protocols using 
tamoxifen. The hypothesis tested stated that exercise 
would have a broad inhibition on both estrogen-dependent 
and independent tumor cells; tamoxifen would have an 
influence on tumor growth and development with a greater 
effect on the estrogen-dependent tumors; and the two 
regimens in combination would have an additive effect on 
the inhibition of mammary tumor induction and growth. 
Though the moderate exercise regimen failed to 
significantly inhibit tumor growth and development when 
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compared with the tamoxifen protocol, the indication of a 
selection toward estrogen-dependent tumors does suggest 
that exercise does in some way influence the development 
of the mammary tumors. Despite the endocrine-based 
classification of the tumors, it is not clear whether 




The objective of this study was to establish the 
influence of a moderate exercise regimen on the induction 
and growth on the induced estrogen-dependent and 
independent rat mammary tumors. Examination of the hypo-
thesis shows that the results of the" experiment were 
different from the projections. The moderate exercise 
regimen did not inhibit tumor growth and appeared to 
select against estrogen-independent tumors. The 
tamoxifen protocol did significantly inhibit tumorgenesis 
but did not select for independent tumors. Finally, the 
combination prophylaxis demonstrated no additive tumor 
inhibition. In this study, moderate exercise in 
prophylaxis demonstrated no tumor inhibition and a 
selective pressure favoring estrogen-dependent tumors. 
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